Amivantamab plus Lazertinib in Previously Untreated <em>EGFR</em>-Mutated Advanced NSCLC

CONCLUSIONS: Amivantamab-lazertinib showed superior efficacy to osimertinib as first-line treatment in EGFR-mutated advanced NSCLC. (Funded by Janssen Research and Development; MARIPOSA ClinicalTrials.gov number, …